136 related articles for article (PubMed ID: 37652819)
1. Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient.
França TF; Gontijo JRV; Junior EFV; Lima EM
An Bras Dermatol; 2024; 99(1):158-160. PubMed ID: 37652819
[No Abstract] [Full Text] [Related]
2. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
3. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
4. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
5. Maintenance of clinical response after short treatment with cemiplimab for advanced squamous cell carcinoma.
Conforti C; Toffoli L; Agozzino M; Fedele D; Moroso S; di Meo N; Zalaudek I
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e443-e445. PubMed ID: 35037322
[No Abstract] [Full Text] [Related]
6. Dichotomic response patterns to PD-1 blockade with cemiplimab in a patient with multiple squamous cell carcinomas.
Bazzacco G; Zelin E; Toffoli L; Conforti C; di Meo N; Fedele D; Zalaudek I
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e547-e549. PubMed ID: 36305888
[No Abstract] [Full Text] [Related]
7. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma.
Geidel G; Adam L; Rünger A; Menz A; Kött J; Haalck T; Gebhardt C
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1414-e1416. PubMed ID: 37458533
[No Abstract] [Full Text] [Related]
8. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
Vasilev P; Kalev D; Karamanliev M; Dimitrov D; Troyanova P; Yordanova I
J Dtsch Dermatol Ges; 2023 Mar; 21(3):295-297. PubMed ID: 36855845
[No Abstract] [Full Text] [Related]
9. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
10. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
11. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
[No Abstract] [Full Text] [Related]
12. Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.
Steren B; Burtness B; Bhatia A; Demirci H; Shinder R; Yoo D; Tse B; Pointdujour-Lim R
Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):496-502. PubMed ID: 35502804
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
[No Abstract] [Full Text] [Related]
14. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
15. Safety of cemiplimab for advanced cutaneous squamous cell carcinoma in a patient with p-ANCA-associated vasculitis.
Pham JP; Sivasubramaniam V; Gallagher R; Forstner D; Wong M; Liu J
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e363-e365. PubMed ID: 36226470
[No Abstract] [Full Text] [Related]
16. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
Gambichler T; Hessam S; Lüttringhaus T; Boms S
Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
[TBL] [Abstract][Full Text] [Related]
17. Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis.
Di Raimondo C; Rao L; Lozzi F; Lombardo P; Silvaggio D; Vellucci L; Tofani L; Campione E; Bianchi L
Dermatol Ther; 2022 May; 35(5):e15421. PubMed ID: 35249252
[No Abstract] [Full Text] [Related]
18. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.
Ali SA; Arman HE; Patel AA; Birhiray RE
JCO Oncol Pract; 2020 Mar; 16(3):137-138. PubMed ID: 31770056
[No Abstract] [Full Text] [Related]
19. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.
Deinlein T; Lax SF; Schwarz T; Giuffrida R; Schmid-Zalaudek K; Zalaudek I
Eur J Cancer; 2017 Sep; 83():99-102. PubMed ID: 28734147
[No Abstract] [Full Text] [Related]
20. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
